{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021747","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.606924+00:00","generated_at":"2026-06-15T02:17:53.159562+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Larimar Therapeutics stockholders elect three Class III directors at 2023 annual meeting","bullets":["Elected Frank Thomas, Carole S. Ben-Maimon, and Joseph Truitt as Class III directors until 2026.","Advisory say-on-pay vote approved with 35.5M votes for, 337.9K against.","Ratified PricewaterhouseCoopers as independent auditor for FY2023 (40.8M for).","Broker non-votes of ~4.9M on director elections and say-on-pay."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021747","json":"https://secwatch.observer/filing/0000950170-23-021747.json","markdown":"https://secwatch.observer/filing/0000950170-23-021747.md","text":"https://secwatch.observer/filing/0000950170-23-021747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/0000950170-23-021747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/lrmr-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:17:53.159562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"073154198f23b976c766a044565053dd374476f9","claim":"Larimar Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2022 at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 2 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2022. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers in 2022, as follows: Votes For Votes Against Abstentions Broker Non-Votes 35,507,612 337,895 55,741 4,876,931","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/0000950170-23-021747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"6219c9317a4af01aa79f9bf1a5063a8ce0b1eba9","claim":"Larimar Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 3 – Ratification of Independent Registered Public Accountant. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 40,769,530 6,201 2,448 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/0000950170-23-021747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"e81ba834fb85ef925614fecac6b9d76979c551b5","claim":"Larimar Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 1 – Election of Class III Directors. Frank Thomas, Carole S. Ben-Maimon, M.D. and Joseph Truitt were elected to the Board of Directors of the Company as Class III directors to serve until the Company’s 2026 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes Frank Thomas 27,741,876 8,159,372 4,876,931 Carole S. Ben-Maimon, M.D. 27,757,513 8,143,735 4,876,931 Joseph Truitt 27,378,190 8,523,058 4,876,931","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021747/0000950170-23-021747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}